ZTEK Stock Chart & Stats
$0.53
$0.04(6.88%)
At close: 4:00 PM EDT
$0.53
$0.04(6.88%)
Day’s Range― - ―
52-Week Range$0.37 - $1.24
Previous Close$0.59
Volume91.31K
Average Volume (3M)63.87K
Market Cap
$76.53M
Enterprise Value$60.34
Total Cash (Recent Filing)$16.60M
Total Debt (Recent Filing)$1.93M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding126,619,530
10 Day Avg. Volume35,879
30 Day Avg. Volume63,873
Financial Highlights & Ratios
PEG Ratio1.44
Price to Book (P/B)7.78
Price to Sales (P/S)459.28
P/FCF Ratio-13.21
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest LeverageLow leverage reduces near-term solvency pressure and interest-related strain, giving Zentek more flexibility to fund research, commercialization, and partnerships while it works toward sustainable revenue.
Diversified Nanotechnology ApplicationsA portfolio serving multiple end markets can broaden the company’s addressable opportunity and reduce dependence on one application. Direct sales, licensing, and partnerships also provide several potential commercialization routes.
Cash Burn Tracks Reported LossesAlthough cash generation is weak, the alignment between cash burn and reported losses makes the financial profile more transparent. This may help management and investors assess funding needs without major hidden working-capital effects.
Bears Say
Severe Revenue VolatilitySharp revenue contraction indicates limited and inconsistent commercialization. Persistently volatile sales make it difficult to establish operating scale, forecast cash requirements, or demonstrate durable customer adoption across the product portfolio.
Persistent Operating LossesContinued losses and deteriorating margins show that current sales do not cover the cost base. Without stronger commercialization or meaningful cost improvement, the company may struggle to convert its technology pipeline into a sustainable business.
Cash Burn And Eroding EquityPersistent cash deficits imply continuing funding needs, while declining equity reflects the cumulative effect of losses and potential capital depletion. This can constrain investment capacity and increase reliance on future financing or dilution.
Zentek News
ZTEK FAQ
What was Zentek’s price range in the past 12 months?
Zentek lowest stock price was $0.37 and its highest was $1.24 in the past 12 months.
What is Zentek’s market cap?
Zentek’s market cap is $76.53M.
When is Zentek’s upcoming earnings report date?
Zentek’s upcoming earnings report date is Nov 16, 2026 which is in 89 days.
How were Zentek’s earnings last quarter?
Zentek released its earnings results on Aug 14, 2026. The company reported -$0.013 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Zentek overvalued?
According to Wall Street analysts Zentek’s price is currently Overvalued.
Does Zentek pay dividends?
Zentek does not currently pay dividends.
What is Zentek’s EPS estimate?
Zentek’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zentek have?
Zentek has 126,619,530 shares outstanding.
What happened to Zentek’s price movement after its last earnings report?
Zentek reported an EPS of -$0.013 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.785%.
Which hedge fund is a major shareholder of Zentek?
Currently, no hedge funds are holding shares in ZTEK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentek Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 154.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $500.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
60.59%
Trailing 12-Months
Company Description
Zentek
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops synthesize graphene, graphene oxide, and graphene quantum dots for applications of graphene. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Thunder Bay, Canada.
Technical Analysis
Arch Biopartners
―
BioMark Diagnostics
―
Medexus Pharmaceuticals Inc
―
―
Sona Nanotech Inc
―
Ownership Overview
1.54% Insiders
0.04% Mutual Funds
2.11% Other Institutional Investors
96.31% Public Companies and
Individual Investors